News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,752 Results
Type
Article (14901)
Company Profile (299)
Press Release (266546)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79894)
Career Advice (162)
Deals (13354)
Drug Delivery (39)
Drug Development (50703)
Employer Resources (31)
FDA (5845)
Job Trends (5172)
News (145163)
Policy (10079)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21778)
ALS (124)
Alzheimer's disease (1031)
Antibody-drug conjugate (ADC) (241)
Approvals (6039)
Artificial intelligence (259)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4565)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (344)
Cancer (3129)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43674)
Collaboration (1148)
Company closure (2)
Compensation (592)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4320)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1381)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (214)
Earnings (31656)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51690)
Executive appointments (621)
FDA (7593)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (487)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6612)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7352)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2674)
Medtech (2683)
Mergers & acquisitions (6625)
Metabolic disorders (724)
Multiple sclerosis (103)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1951)
Neurotech (1)
NextGen: Class of 2026 (2041)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (329)
Peanut (43)
People (26672)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15474)
Phase 2 (20291)
Phase 3 (12824)
Pipeline (3248)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (648)
Real estate (1447)
Recruiting (12)
Regulatory (9901)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (14)
Last 7 days (337)
Last 30 days (1128)
Last 365 days (17810)
2026 (1665)
2025 (18098)
2024 (20546)
2023 (22415)
2022 (26823)
2021 (27809)
2020 (23367)
2019 (16237)
2018 (11753)
2017 (13752)
2016 (11840)
2015 (14359)
2014 (10401)
2013 (7499)
2012 (7548)
2011 (7627)
2010 (7439)
Location
Africa (155)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18253)
Australia (3112)
California (7074)
Canada (1837)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39174)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5583)
Michigan (110)
Minnesota (248)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1646)
New Mexico (13)
New York (1762)
North Carolina (827)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (216)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (905)
United States (23332)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,752 Results for "dyne therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
Dyne’s Exon Skipper Delivers ‘Best Ever’ Functional Outcomes in Early DMD Study
Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for this treatment class, Stifel analysts said.
December 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
January 20, 2026
·
7 min read
Rare diseases
Dyne Primed for Suitors Amid Novartis’ $12B Avidity Acquisition
The takeover of its competitor, announced Sunday, could also bring some attention to Dyne Therapeutics, which has a similar RNA-based pipeline in rare muscle diseases.
October 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
December 24, 2025
·
6 min read
Press Releases
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
·
1 min read
Press Releases
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
December 10, 2025
·
4 min read
Press Releases
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
September 30, 2025
·
7 min read
Press Releases
Dyne Therapeutics to Present at Upcoming Investor Conferences - November 3, 2025
November 4, 2025
·
1 min read
Press Releases
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025
·
11 min read
Press Releases
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
December 12, 2025
·
2 min read
1 of 28,176
Next
